Virax Biolabs Group Limited has scheduled its 2024 Annual General Meeting for December 12, 2024. Shareholders will vote on four key proposals: ratifying Reliant CPAs PC as auditor, re-electing five current directors, approving the 2024 Equity Incentive Plan, and authorizing potential meeting adjournment.The company seeks to re-elect James Foster, Nigel McCracken, Yair Erez, Evan Norton, and Nelson Haight as directors. The proposed 2024 Equity Incentive Plan would reserve 250,000 ordinary shares for issuance, allowing for various equity awards to attract and retain key personnel.Shareholders of record as of October 14, 2024, are eligible to vote. The meeting will be held at BioCity Glasgow, with options for in-person attendance and proxy voting. The Board recommends voting 'FOR' all proposals.

Virax Biolabs Group Limited has scheduled its 2024 Annual General Meeting for December 12, 2024. Shareholders will vote on four key proposals: ratifying Reliant CPAs PC as auditor, re-electing five current directors, approving the 2024 Equity Incentive Plan, and authorizing potential meeting adjournment.The company seeks to re-elect James Foster, Nigel McCracken, Yair Erez, Evan Norton, and Nelson Haight as directors. The proposed 2024 Equity Incentive Plan would reserve 250,000 ordinary shares for issuance, allowing for various equity awards to attract and retain key personnel.Shareholders of record as of October 14, 2024, are eligible to vote. The meeting will be held at BioCity Glasgow, with options for in-person attendance and proxy voting. The Board recommends voting 'FOR' all proposals.